You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 26411 results
  1. A.

    SBC: C-MOTION, INC.            Topic: N/A

    A. WE PROPOSE TO DEVELOP A METHODOLOGY BY WHICH THE GENES CODING FOR DISEASE-SPECIFIC ANTIGENS CAN BE RAPIDLY CLONED USING RECOMBINANT DNA TECHNIQUES. THE SYSTEM LENDS ITSELF TO HIGH LEVEL EXPRESSION OF THESE ANTIGENS AS HYBRID PROTEINS, WHICH FACILITATES PRODUCTION OF ANTIBODIES TO THE ANTIGENS. WITH BOTH ANTIGEN AND ANTIBODY, IMMUNODIAGNOSTIC TESTS CAN BE PRODUCED FOR DETECTION OF THESE ANTIGENS ...

    SBIR Phase I 1984 Department of Health and Human Services
  2. AAAV Composite Armor Systems

    SBC: Q-PEAK INCORPORATED            Topic: N/A

    Diode-laser arrays operating in the visible region of the spectrum offer advantages for illuminator applications, particularly for night and water penetration capability. Recent developments in diode-laser materials allow operation throughout the visiblespectrum. At this time, red diode-laser technology is more mature than the existing blue-green or violet diode-laser technology. The novel aspe ...

    SBIR Phase I 2001 Department of DefenseNavy
  3. A1 adenosine agonist: antinociceptive effects

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The current Phase I SBIR Grant application by Inotek Pharmaceuticals Corporation proposes to test the antinociceptive effect of a novel A1 receptor agonist in rat models. As preliminary data we present evidence in

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. A13: Aptimas Advanced Automated Approach Aimed At Author-Artifact Attribution And Assessing Author Ambitions

    SBC: APTIMA INC            Topic: A18054

    Human social interaction is complicated by ambiguous identities, misinformation, misdirection, and flexible alliances. Additionally, thanks to the internet, authors can post messages from anywhere in the world, in diverse forms, and with different personas. Current solutions are challenged to accurately identify and characterize authors across platforms and data types, let alone infer authorial in ...

    SBIR Phase I 2018 Department of DefenseArmy
  5. AAV-based toolkit for targeting specific cell types

    SBC: NEUROTARGETING SYSTEMS            Topic: NINDS

    DESCRIPTION (provided by applicant): Our goal is to develop an efficient and inexpensive toolkit for ablating or reversibly inactivating specific cell types in the brain or other organs of mammals. We propose new techniques in which the genes for nitroreductase (NTR) or Drosophila allatostatin receptor (AlstR) are delivered into cells using an adeno-associated viral vector (AAV). Both are fusion ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. ABAIS: Affect and Belief Adaptive Interface System

    SBC: PSYCHOMETRIX ASSOCIATES, INC.            Topic: N/A

    Currently, the majority of decision-support systems assume normative performance and fail to adapt to individual differences. This is particularly true with respect to affective states and individual beliefs, which can have profound impact on performance, particularly in complex, crisis situations. We propose to develop an Affect and Belief Adaptive Interface System (ABAIS) capable of compensati ...

    SBIR Phase I 1998 Department of DefenseAir Force
  7. Aberration-correcting Topologically Optimized Metasurface (ATOM)

    SBC: PHYSICAL SCIENCES INC.            Topic: HR001119S003524

    Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
  8. Aberration-correcting Topologically Optimized Metasurface (ATOM)

    SBC: PHYSICAL SCIENCES INC.            Topic: HR001119S003524

    Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight with high performance over a large optical bandwi ...

    STTR Phase II 2021 Department of DefenseDefense Advanced Research Projects Agency
  9. ABIDE: Agent Based Intelligent Decluttering Enhancements

    SBC: APTIMA INC            Topic: N102158

    The Anti-Submarine Warfare Commander (ASWC) has a crucial responsibility to protect against surface and subsurface threats, which requires keeping track of contacts and making safety-critical decisions. The Undersea Warfare Decision Support System (USW-DSS) supports the ASWC and his team by providing a"Common Tactical Picture"via the Master Tactical Plot (MTP). However, evolving sensor and data fu ...

    SBIR Phase I 2011 Department of DefenseNavy
  10. A Bifunctional Katp Channel Activator and Redox Mimetic for BPD

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Radikal Therapeutics is developing a novel small molecule therapy (R-801) for neonatal prematurity that triggers an endogenous cytoprotective defense and thereby blocks pulmonary inflammation and acute lung injury (ALI). R-801 is formed from the covalent fusion of 2 moieties with demonstrated tissue protective properties: 1) a mito-K+-ATP channel activating do ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government